The effect of abiraterone acetate treatment on CREB and the development of abiraterone acetate resistance in prostate cancer cells.

177Background: The androgen receptor (AR) remains an essential target in castration resistant prostate cancer (CRPC). Abiraterone acetate (AA), an inhibitor of CYP17A1, is an FDA approved drug for ...